The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment

1. Study Design This is a single-center, prospective, randomized, controlled, exploratory clinical trial. The study is designed to evaluate and compare the efficacy and safety of two biologic-based induction regimens against standard of care (SOC) and a triple-combination regimen in patients with active proliferative lupus nephritis (LN).
2. Study Objectives Primary Objective: To compare the 6-month complete renal response (CRR) rate among patients receiving biologic-based induction therapy, SOC induction therapy, and triple-combination induction therapy.
Secondary Objectives: To compare the rates of partial renal response (PRR) and overall renal response (ORR) at monthly intervals up to Month 6; to assess the time to achieve CRR/PRR; to evaluate changes in clinical and immunological parameters from baseline; and to compare the safety profiles of the three treatment regimens.
3. Key Eligibility Criteria Patients aged 14-65 years with biopsy-proven active Class III or IV (±V) LN according to ISN/RPS 2018 classification, an SLE-DAI score >6, and 24-hour urine protein >1.0 g/d will be eligible. Key exclusion criteria include an eGFR ≥45 ml/min/1.73m², recent use of renal replacement therapy or potent immunosuppressive procedures, significant concurrent infections, severe hematological/ hepatic abnormalities, and known hypersensitivity to the study biologics.
4. Treatment Groups and Intervention
Eligible patients will be randomized in a 2:2:1 ratio to one of three treatment arms for a 6-month induction period:
Biologics Group (n≈20): Glucocorticoids + either Belimumab or Telitacicept. SOC Group (n≈20): Glucocorticoids + Mycophenolate Mofetil (MMF). Triple Therapy Group (n≈10): Glucocorticoids + MMF + either Belimumab or Telitacicept.
The choice between Belimumab and Telitacicept within the Biologics and Triple Therapy groups will be determined jointly by the investigator and the patient.
5. Study Medications & Administration Glucocorticoids: All patients will receive oral prednisone (or equivalent) starting at 0.5 mg/kg/day (max 40 mg/day), with a mandatory taper to ≤5 mg/day by Month 4 and stable dosing from Months 5-6. Intravenous methylprednisolone pulses are permitted per investigator discretion.
Mycophenolate Mofetil (MMF): Administered only in the SOC and Triple Therapy groups. The target dose is 1.5-2.0 g/day, maintained until the end of the treatment period.
Belimumab: Administered via intravenous infusion at 10 mg/kg (600 mg/dose) every 2 weeks.
Telitacicept: Administered via subcutaneous injection at 160 mg once weekly. Patients in the Biologics or SOC groups showing no response by Month 3 may directly switch to the Triple Therapy regimen.
6. Primary Efficacy Endpoint
The primary endpoint is the proportion of patients achieving Complete Renal Response (CRR) at Month 6. CRR is strictly defined as:
24-hour urine protein <0.5 g/d, AND Estimated Glomerular Filtration Rate (eGFR) ≥85% of the baseline value, AND No requirement for rescue therapy or premature treatment withdrawal. 7. Secondary Efficacy & Safety Assessments Key secondary efficacy assessments include monthly CRR, PRR, and ORR rates; time to response; incidence of renal-related events; and changes in proteinuria, eGFR, serum creatinine, and disease activity scores (SELENA-SLEDAI, BILAG-2004, PGA). Safety will be evaluated through the incidence and severity of adverse events, with special attention to infections, infusion/injection reactions, and metabolic parameters.
8. Statistical Considerations This is an exploratory study with a planned enrollment of 40-50 patients. The primary analysis will use the Full Analysis Set (FAS) under the intention-to-treat principle. The difference in the Month 6 CRR rate among the three groups will be analyzed using the Chi-square test. Time-to-event data will be analyzed using the Kaplan-Meier method with Log-rank test for comparisons.
9. Hypothesis: This study protocol outlines a head-to-head comparison of novel biologic-based induction strategies against current SOC for active LN. It aims to generate critical preliminary data on whether glucocorticoids combined with a biologic (Belimumab or Telitacicept) alone can induce effective renal remission, potentially offering a targeted treatment option with a different safety profile compared to conventional immunosuppressive therapy. The results may inform the design of larger, confirmatory trials in LN management.

Start Date01 Jan 2026

Sponsor / Collaborator

Nanjing University

NCT07138898

/ Not yet recruitingPhase 2IIT

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

The purpose of this study is to assess the incidence of rheumatologic flares, changes in pain scores (VAS), changes in functional outcomes (PROMIS), wound complications, surgical site infections, and return trips to the operating room for rheumatology patients following shoulder replacements, comparing those who stop their immunosuppressants preoperatively for the same amount of time as suggested in the literature for hip and knee arthroplasty versus those who hold the medications for a shorter period of time preoperatively.

Start Date01 Sep 2025

Sponsor / Collaborator

NYU Langone Health

CTIS2023-508116-32-00

/ Not yet recruitingPhase 2IIT

BE-MOBILYZED: BElimumab to MOBIlise memory B-cells from secondary LYmhoid organs to improve memory B-cell HLA-specificity profiling to support delisting for transplant access in highly-sensitiZED.

Start Date01 Sep 2025

Sponsor / Collaborator-

100 Clinical Results associated with Belimumab

100 Translational Medicine associated with Belimumab

100 Patents (Medical) associated with Belimumab

1,221

Literatures (Medical) associated with Belimumab

08 Jan 2026·RHEUMATOLOGY

Belimumab versus calcineurin inhibitors for cancer risk in lupus nephritis

Article

Author: Mahajan, Arjun ; Sparks, Matthew A ; Sparks, Jeffrey A ; Tomasi, Alessandra ; LaChance, Avery ; Whittelsey, Maureen

01 Jan 2026·CURRENT OPINION IN RHEUMATOLOGY

Advances in the diagnosis and treatment of Sjögren disease

Review

Author: Karampela, Asimina I. ; Tsironis, Christos ; Mavragani, Clio P.

Purpose of review:

Sjögren disease (SjD) constitutes a diagnostic and therapeutic challenge due to its clinical heterogeneity and complex pathophysiology. This review synthesizes recent advances in diagnostics, disease stratification, and targeted therapies, highlighting their potential to optimize patient care.

Recent findings:

Emerging diagnostic approaches include advanced salivary, lacrimal, and serum biomarkers, refinements of established diagnostic tools, role of specific autoantibodies, and AI-assisted histopathology, improving early detection and risk stratification, particularly for lymphoma-prone phenotypes. Novel immunological insights have enabled phenotype-based classification, guiding the development of targeted therapies against B-cell pathways, cytokines, and co-stimulatory molecules with several agents (e.g., belimumab, ianalumab, telitacicept) showing promise in reducing disease activity scores.

Summary:

Recent advances provide a framework for precision medicine in SjD, integrating molecular and imaging biomarkers into patient selection and treatment monitoring. Clinically, this could enable earlier diagnosis, individualized risk assessment, and tailored therapy. Research priorities now include validating diagnostic innovations in diverse populations, elucidating phenotype-specific mechanisms, and conducting adequately powered, biomarker-driven trials to optimize therapeutic efficacy.

01 Jan 2026·ANNALS OF THE RHEUMATIC DISEASES

Differential molecular signatures in response to CD19-CAR T cell therapy compared with conventional pharmacotherapy in systemic lupus erythematosus

Article

Author: Hagen, Melanie ; Mackensen, Andreas ; Bertsias, George ; Schett, Georg ; Lindblom, Julius ; Grieshaber-Bouyer, Ricardo ; Garantziotis, Panagiotis ; Wirsching, Andreas ; Moysidou, Georgia-Savina ; Boumpas, Dimitrios T ; Parodis, Ioannis ; Bozec, Aline ; Alarcón-Riquelme, Marta E ; Bergmann, Christina ; Schneider, Matthias ; Nikolopoulos, Dionysis ; Barturen, Guillermo ; Beretta, Lorenzo

OBJECTIVES:

Early trials of CD19-chimeric antigen receptor (CAR) T cell therapy in systemic lupus erythematosus (SLE) show promise, but the molecular mechanisms underlying its disease-modifying effects remain unclear. We aimed to compare biological profiles and alterations following CD19-CAR T cell versus standard pharmacotherapy in SLE.

METHODS:

Pseudo-bulk gene expression derived from single-cell RNA sequencing of peripheral blood mononuclear cells from 7 SLE patients before and after CD19-CAR T cell therapy was compared with whole-blood transcriptome data from 30 SLE patients in remission on standard pharmacotherapy and 31 SLE patients before and 6 months after treatment with rituximab, belimumab, or cyclophosphamide. Pathway analysis was conducted using Functional Analysis of Individual Microarray Expression and gene set enrichment analysis.

RESULTS:

CD19-CAR T cell-induced remission was characterised by marked suppression of complement activation, type I interferon, DNA damage response (DDR), and cell death pathways compared with remission following conventional pharmacotherapy, alongside an upregulation of lipid metabolism pathways. Compared with rituximab and belimumab, CD19-CAR T cell therapy induced greater downregulation of type I/II interferon, DDR, and chemokine pathways. Compared with cyclophosphamide, CD19-CAR T cell therapy induced greater suppression of interferon, mitochondrial, and mammalian target of rapamycin signalling pathways.

CONCLUSIONS:

CD19-CAR T cell therapy induces substantial suppression of key immunological pathways involved in SLE, including complement activation and type I interferon responses, accompanied by a metabolic reprogramming. Molecular profiles of remission after CD19-CAR T cell therapy differ from those induced by conventional SLE pharmacotherapy, suggesting more profound CD19-CAR T cell-induced biological alterations.

109

News (Medical) associated with Belimumab

06 Jan 2026

·www.fiercepharma.com

AZ looks to grow reach in lupus with phase 3 win for self-administered Saphnelo

The full results from AstraZeneca's phase 3 Tulip-SC trial build on the interim results that earned the drug a European approval last month. Fresh off of a European approval for a subcutaneous version of Saphnelo, AstraZeneca is doubling down on the benefits of the self-administered drug formulation in lupus patients with a positive phase 3 showing.In the phase 3 Tulip-SC trial, 56.2% of patients with systemic lupus erythematosus (SLE) who received a subcutaneous dose of Saphnelo experienced a reduction in disease activity at week 52, the company reported Tuesday. In the placebo group, the result was 37.1%.The readout adds more detail to the trial's prior interim analysis, which confirmed a statistically significant result for subcutaneous Saphnelo and a safety profile on par with the currently marketed intravenous infusion version. Subcutaneous Saphnelo also met the bar across a range of secondary endpoints in the trial, many of which use the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) as a measure of disease activity.AstraZeneca found that more patients (41.5%) achieved a faster BICLA response with SC Saphnelo than with placebo, and that those in the treatment group had a longer delay to their first disease flare-up.Additional pre-specified secondary and exploratory endpoints, 40.1% of patients on treatment attained low-level disease activity and 29% achieved DORIS remission at week 52, as did 14.7% on placebo. Recently revised treatment guidance for SLE positions DORIS remission, which is a remission definition established by the DORIS Task Force, as the primary goal of care, AstraZeneca notes.“These results reinforce Saphnelo’s unique approach of targeting the type 1 interferon receptor to reduce disease activity, with the added convenience of subcutaneous self-administration,” Sharon Barr, EVP of R&D at AstraZeneca, said in a company release. “The TULIP-SC findings build on the compelling body of evidence for Saphnelo, which has helped patients achieve remission and significantly reduce reliance on oral corticosteroids—further reinforcing our ambition to transform lupus care.” Tapering toward chronic oral corticosteroids (OCS) discontinuation is another recent addition to lupus treatment recommendations, putting AZ’s results in line with the key changes to the global standards, the company explained in the release. Saphnelo, as an IV infusion, won FDA approval in 2021, breaking a 10-year treatment drought in SLE after GSK’s 2011 nod for Benlysta. The nod came after a phase 3 trial found that Saphnelo didn’t outperform placebo on a disease response measure called the SLE Responder Index 4, prompting AZ to pivot to the BICLA marker for its next study.Over 3.4 million people globally are impacted by SLE, and the disease is one of the leading causes of death in young women in the U.S., according to the company. AZ hopes to reach more of those patients through its more convenient, subcutaneous version of Saphnelo. European regulators were the first to approve Saphnelo as a once-weekly, pre-filled pen in December, while regulatory applications in other countries, including the U.S. and Japan, are under review.The new formulation could be key to catching up with GSK’s Benlysta, which was approved as a self-injectable treatment option in 2017. With a ten-year lead on Saphnelo, Benlysta remains the one to beat in the SLE field, touting blockbuster sales in 2024 compared to Saphnelo’s $474 million.However, Spherix Global Insights analysts note that the lupus treatment landscape is “poised for evolution,” noting that Biogen’s experimental litifilimab is an “especially strong competitor” to the two existing offerings from AZ and GSK.

Clinical ResultPhase 3Drug Approval

06 Jan 2026

·www.prnewswire.com

Lupus Research Alliance Launches New Philanthropic Fund to Advance Treatments and Diagnostics

The Fund Will be Managed by Experienced Life Sciences Investor Nishant Rastogi NEW YORK, Jan. 6, 2026 /PRNewswire/ -- Today, the Lupus Research Alliance, the world's largest private funder of lupus research, announced the formation of a new philanthropic venture fund Lupus Ventures. The Fund is dedicated to advancing treatments and diagnostics for systemic lupus erythematosus (SLE), its manifestations, and related autoimmune conditions. Continue Reading Lupus Ventures aims to accelerate the development of new treatments and diagnostics that can improve the standard of care and deliver meaningful value to the millions of people living with lupus worldwide. Lupus is a chronic, complex autoimmune disease that affects millions of people worldwide. Treatment development stagnated for years after the U.S. Food and Drug Administration approved Benlysta® in 2011. However, with the approvals of Saphnelo® and Lupkynis® in 2021, and Gazyva® in October 2025, the tides are turning. Innovative treatments like engineered cell therapies are showing great promise, and there are over 140 lupus therapies in clinical trials today from more than 120 companies. With that promise, philanthropic investment in higher-risk, early-stage companies is increasingly powerful. Lupus Ventures aims to bridge the gap between innovative science and commercial reality. "The Lupus Research Alliance has spent years building a research engine that supports every part of the scientific process — from basic and translational research through clinical development," Albert T. Roy, President & CEO of the Lupus Research Alliance, said. "Launching Lupus Ventures is the natural — and critical — next step. It allows us to strategically deploy resources and catalyze solutions for people living with lupus, ensuring promising ideas don't sit on a shelf simply for lack of funding." Nishant Rastogi will serve as the Fund's inaugural Managing Director. Mr. Rastogi is an accomplished life sciences investor with more than a decade of biotech venture capital and private equity experience. He has served as a Board Director and operating partner for multiple biotech and medtech companies throughout his career. Before joining Lupus Ventures, Mr. Rastogi served as Vice President and Head of Transactions at New Rhein Healthcare Investors. He played an integral role in all aspects of the firm's evolution and growth — including investment activities, portfolio management, team building, and operations. He was involved in New Rhein's investments in Corsair (Director), Theranica, Alveus, American Injectables, Butterfly Medical, Softhale (acquired), Neuraptive, and others. Earlier in his career, Mr. Rastogi was an investor at Broadview Ventures and an analyst at Fidelity Investments. He has advised several disease research foundations — including Beyond Celiac, 90/10 Institute, and Parent Project Muscular Dystrophy — on venture fund formation and the role of philanthropy and private investment in advancing new medicines and health equity. Mr. Rastogi earned his BA from Dartmouth College and his MBA from Northwestern University. "I am grateful to the Lupus Research Alliance for the opportunity to build this platform," Mr. Rastogi said. "As the world's only investment fund dedicated to SLE, we are uniquely positioned to support companies developing potential therapies in this area to benefit people living with lupus globally. The combination of recent scientific advancements and investor and industry interest makes this a perfect time to launch the Fund." All companies — regardless of modality or stage of development — are being considered for investment. In addition to capital, the companies will also receive counsel and guidance, leveraging the Lupus Research Alliance's depth of knowledge gained through its industry leadership. To date, the Lupus Research Alliance has awarded more than $284 million across 650+ research grants, and clinical affiliate Lupus Therapeutics is involved in 25-30% of active clinical trials. The Fund will be overseen by the Investment Committee that includes Mr. Rastogi, Mr. Roy and Ira Akselrad, President and CEO of The Johnson Company, Inc. and Chair of the Lupus Research Alliance Board of Directors. Teodora Staeva, PhD, Chief Scientific Officer of the Lupus Research Alliance, will serve on its Scientific Advisory Board. The Fund plans to recruit additional experts to the Investment Committee, Scientific Advisory Board, and investment team in 2026. To learn more about Lupus Ventures, visit . About Lupus Lupus is a chronic, complex autoimmune disease that affects millions of people worldwide. In lupus, the immune system, meant to defend against infections, produces autoantibodies that mistake the body's own cells as foreign, causing other immune cells to attack organs such as the kidneys, brain, heart, lungs, and skin, as well as blood and joints. Ninety percent of people with lupus are women, most often diagnosed between the ages of 15-45. Black, Latinx, Indigenous, Asian and Pacific Islander people are disproportionately affected by lupus. About Lupus Ventures Lupus Ventures (dba "The Lupus Venture Fund") is the venture investment fund of the Lupus Research Alliance. The Fund is dedicated to advancing treatment and diagnostic options for systemic lupus erythematosus (SLE), its manifestations, and related autoimmune conditions. The Fund defines success as improving the standard of care and delivering meaningful value to the millions of people living with lupus worldwide. Visit for more information. About the Lupus Research Alliance The Lupus Research Alliance is the largest non-governmental, non-profit funder of lupus research worldwide. The organization aims to transform treatment by funding the most innovative lupus research, fostering scientific talent, and driving discovery toward better diagnostics, improved treatments and, ultimately, a cure for lupus. Because the Lupus Research Alliance's Board of Directors funds all administrative and fundraising costs, 100% of all donations goes to support lupus research programs. For more information or to donate to lupus research, visit the LRA at LupusResearch.org and on social media at: X, Facebook, LinkedIn, and Instagram. SOURCE Lupus Research Alliance 21% more press release views with Request a Demo

Drug ApprovalExecutive Change

06 Jan 2026

·firstwordpharma.com

AstraZeneca details data for lupus injection as J&J's contender heads to Phase III

AstraZeneca and J&J each reported systemic lupus erythematosus (SLE) data for their respective therapeutics on Tuesday, with the former hoping to make an impact with a new subcutaneous (SC) formulation of Saphnelo (anifrolumab).The UK pharma laid out detailed Phase III data showing that Saphnelo (anifrolumab) can significantly reduce disease activity and steroid dependence. Full results from the Phase III TULIP-SC study, toplined in September, were recently published in Arthritis & Rheumatology and come on the heels of a green light for the SC option by EU regulators.In the 367-patient study, 56.2% of patients receiving Saphnelo SC achieved a reduction in disease activity at 52 weeks based on British Isles Lupus Assessment Group–based Composite Lupus Assessment (BICLA), compared to 37.1% for placebo. The 19.1-percentage-point difference was statistically significant and consistent with prior intravenous trials, the company said.Reduced steroid useSaphnelo also demonstrated "clinically meaningful" effects across key secondary measures. AstraZeneca said 56.2% patients on Saphnelo SC were able to maintain low or reduced oral steroid doses versus 34% on placebo; 41.5% achieved a BICLA response that lasted through 52 weeks versus 22.6%; and fewer patients flared over a year (40.9% vs 48.5%), though that difference wasn't statistically significant."The results align with important changes in global lupus treatment recommendations, which now emphasise earlier intervention with biologics, driving remission and reduced use of oral corticosteroids as key treatment goals," said Susan Manzi, principal investigator of TULIP-SC.The ability for patients to self-administer Saphnelo outside clinical settings marks a strategic shift for AstraZeneca, which already markets the intravenous formulation for moderate-to-severe SLE in more than 70 countries. Saphnelo SC remains under regulatory review in the US and Japan.If approved, it would compete more directly with GSK's Benlysta (belimumab), which gained separate US and European nods in 2017 for its self-injectable version based on the BLISS-SC study, where 60.8% of patients achieved a response on the SLE Responder Index (SRI) after 52 weeks, versus 48.5% for placebo.Broadening nipocalimab scopeMeanwhile, J&J reported positive topline data from its Phase IIb JASMINE study of nipocalimab, saying its drug is the first FcRn blocker to demonstrate activity in active SLE.The 228-patient study met its primary endpoint, with significantly more patients achieving SRI-4 response at 24 weeks compared to placebo, as well as key secondary and exploratory endpoints, including those indicating possible steroid-sparing effects, according to the company.On the strength of those results, J&J said it will launch a Phase III programme in SLE. The FDA last year approved the drug under the name Imaavy in generalised myasthenia gravis.Nipocalimab is also in development for other autoimmune diseases, including haemolytic disease of the foetus and newborn, warm autoimmune haemolytic anaemia, chronic inflammatory demyelinating polyneuropathy and Sjögren's disease, though last year J&J scrapped a mid-stage combo trial of the drug in rheumatoid arthritis after underwhelming results.

Clinical ResultPhase 3Phase 2Drug Approval

100 Deals associated with Belimumab

External Link

KEGG	Wiki	ATC	Drug Bank
D03068	Belimumab	L04AA26	DB08879

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Lupus Nephritis	European Union	GlaxoSmithKline Trading Services Ltd.	13 Jul 2011
Lupus Nephritis	Iceland	GlaxoSmithKline Trading Services Ltd.	13 Jul 2011
Lupus Nephritis	Liechtenstein	GlaxoSmithKline Trading Services Ltd.	13 Jul 2011
Lupus Nephritis	Norway	GlaxoSmithKline Trading Services Ltd.	13 Jul 2011
Systemic Lupus Erythematosus	United States	GlaxoSmithKline LLC	09 Mar 2011

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Scleroderma, Systemic	Phase 3	United States	GSK Plc	12 Dec 2024
Scleroderma, Systemic	Phase 3	China	GSK Plc	12 Dec 2024
Scleroderma, Systemic	Phase 3	Japan	GSK Plc	12 Dec 2024
Scleroderma, Systemic	Phase 3	Argentina	GSK Plc	12 Dec 2024
Scleroderma, Systemic	Phase 3	Australia	GlaxoSmithKline (Ireland) Ltd.	12 Dec 2024
Scleroderma, Systemic	Phase 3	Belgium	GlaxoSmithKline (Ireland) Ltd.	12 Dec 2024
Scleroderma, Systemic	Phase 3	Brazil	GlaxoSmithKline (Ireland) Ltd.	12 Dec 2024
Scleroderma, Systemic	Phase 3	Denmark	GlaxoSmithKline (Ireland) Ltd.	12 Dec 2024
Scleroderma, Systemic	Phase 3	Finland	GlaxoSmithKline (Ireland) Ltd.	12 Dec 2024
Scleroderma, Systemic	Phase 3	France	GlaxoSmithKline (Ireland) Ltd.	12 Dec 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05917288 (CTgov)	Phase 1	Systemic Lupus Erythematosus	16	Belimumab (Belimumab 200 mg/mL Every Week)	viqwqhnpvj(bftbytcott) = bcblsjziiq hxtyabsnyw (fbywmemuun, 27.50) View more	-	14 Nov 2025
				Belimumab (Belimumab 200 mg/mL Every 10 Days)	zoeulpkeiq(qoqdpmzdfp) = fabudkvide jkbyeyqcvq (gwduerghzh, 17.44) View more
NCT04515719 (Ann Rheum Dis) Manual	Phase 4	Systemic Lupus Erythematosus	231	BelimumabBelimumab 120 mg + SOC	riobzpwocp(pdbudrslfi) = bkhkxmucwj fzdxgjynih (assrrzrdnm ) Met View more	Positive	06 Nov 2025
				Placebo (saline) + SOC	riobzpwocp(pdbudrslfi) = kxvoctejaj fzdxgjynih (assrrzrdnm ) Met View more
NCT04515719 (Pubmed \| Ann Rheum Dis)	Phase 4	Systemic Lupus Erythematosus	231	Low-dose belimumab	sfnntxfdmr(akseaftqng) = saxvrcvcfj lgkyxesybd (ypkhheiipu ) View more	Positive	01 Nov 2025
				Placebo (saline)	sfnntxfdmr(akseaftqng) = umndlfbice lgkyxesybd (ypkhheiipu ) View more
NCT04515719 (ACR2025) Manual	Phase 4	Systemic Lupus Erythematosus	231	BelimumabBelimumab 120mg + Standard of Care	cigmoldybv(rpssyltddu) = xdigmwqkdr kphcgjbfnf (tujtkosikr ) Met View more	Positive	24 Oct 2025
				Placebo + Standard of Care	cigmoldybv(rpssyltddu) = hwsovxghfe kphcgjbfnf (tujtkosikr ) Met View more
RELIABLE (ACR2025)	Not Applicable	Systemic Lupus Erythematosus	400	Belimumab	dofwntwqzm(moaifewxgm) = wnlgymgxpo pmwishczpm (scvfjbrarc ) View more	Positive	24 Oct 2025
ACR2025	Not Applicable	Lupus Nephritis	38	Belimumab-Based Triple Therapy	fyuizlgdvk(rrwckzhvsb) = woiclicixk rkgnwmuqvq (qxivypjpzx ) View more	Positive	24 Oct 2025
NCT01639339 (BLISS-LN, ACR2025)	Phase 3	Lupus Nephritis	271	Belimumab	pjieriuzpu(fldmqzohvc) = qipenryvhl bllxtafukj (rpsghmcwej )	Positive	24 Oct 2025
				Placebo	pjieriuzpu(fldmqzohvc) = snzugdloqw bllxtafukj (rpsghmcwej )
ACR2025	Not Applicable	Systemic Lupus Erythematosus	2,841	Belimumab	rgfbsevzvk(ilscgtnxmd): HR = 0.45 (95.0% CI, 0.26 - 0.8)	Positive	24 Oct 2025
				Azathioprine
NCT00424476 (BLISS-52, ACR2025)	Phase 3	Systemic Lupus Erythematosus	910	Belimumab+Antimalarials+Glucocorticoids	bkhyyzyriw(tgvqqutgfu) = csfqaglmdo wjhxllsmgg (fenqiphtuu ) View more	Positive	24 Oct 2025
				Immunosuppressants+Antimalarials+Glucocorticoids	bkhyyzyriw(tgvqqutgfu) = ljezfktpbl wjhxllsmgg (fenqiphtuu ) View more
ACR2025	Not Applicable	Systemic Lupus Erythematosus anti-SSA \| anti-SSB \| anti-Jo-1 ... View more	125,675	Belimumab	lmvesebgnt(otofhkbeyg) = unjloplgop cakoteiuss (xazeyqzzmt ) View more	Negative	24 Oct 2025
				Anifrolumab	ydgwbyvera(pvipkozeqj) = xnnmytawrj pwoksgrtla (fakhmdpbvt ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis